Recruiting

Precision Oncology

Sponsor:

Indiana University

Code:

NCT06081517

Conditions

Metastatic Cancer

Advanced Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Social Determinants of Health and toxicity questionnaires

Study Details

Brief summary:

This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

Conditions

Metastatic Cancer

Advanced Cancer

Study ID

NCT06081517

Start date

Jan 26, 2024

Status verified date

Jun, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Ability to provide written informed consent and HIPAA authorization
2. Patients must be ≥ 18 years old at the time of consent
3. Patients who have or are planning to undergo molecular testing as part of their routine cancer care

Exclusion Criteria:

N/A

Study Design

Enrollment

10600 participants

Anticipated

Interventions and Outcome Measures

Arms

Black patients with advanced cancer

Non Black patients with advanced cancer

Interventions

Social Determinants of Health and toxicity questionnaires

Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.

Primary outcome measure

  • Compare Overall Survival between Black patients and White patients (self-reported race) with advanced cancer [ Time Frame: through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years ]
  • Compare rate of new onset or worsening therapy- induced peripheral neuropathy (TIPN) between Black patients and White patients with advanced cancer prospectively exposed to a taxane [ Time Frame: through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years ]

Central Contacts and Locations

Central contacts

Maria McQuade, BA

(317) 278-5238mcquadem@iu.edu

Bryan P Schneider, MD

317-948-3855bpschnei@iu.edu

Locations

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Maria McQuade, BA

(317) 278-5238mcquadem@iu.edu

Principal Investigator:

Bryan Schneider, MD

More Information

Sponsor

Indiana University

Last update posted

Jun 16, 2026

Last verified

Jun, 2026

Keywords

  • Precision Medicine
  • Disparities

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Indiana University on 2026-06-16.